BiotechTube

SBT777101

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Mar 6, 2024 → Mar 1, 2026

NCT ID
NCT06201416

About SBT777101

SBT777101 is a phase 1 stage product being developed by Sonoma Pharmaceuticals for Rheumatoid Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06201416. Target conditions include Rheumatoid Arthritis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06361836Phase 1Active
NCT06201416Phase 1Recruiting

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
TilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
44
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
77
LY2127399Eli LillyPhase 3
77
Baricitinib + TNF InhibitorEli LillyApproved
85
CT-P17 SC AI (adalimumab)CelltrionPhase 3
77
Remsima IV + Remsima SCCelltrionPre-clinical
23
CT-P13 + RemicadeCelltrionPhase 3
77
CT-P47 + EU-approved RoActemraCelltrionPhase 3
77
InfliximabCelltrionPhase 3
77
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Rituximab, MTX, folic acidCelltrionPhase 1
33
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
77
rituximabCelltrionPhase 1
33
CT-P17 SC + Humira SCCelltrionPhase 3
77
AdalimumabCelltrionPre-clinical
23
InfliximabCelltrionPhase 3
77

Other Products from Sonoma Pharmaceuticals

SBT115301 + PlaceboPhase 1
25
SBT777101Phase 1
25